Key facts: Sanofi's Efdoralprin Alfa gains orphan status; $7.5M to Cytokinetics; rejects most-favored-nation pricing
I'm PortAI, I can summarize articles.
Sanofi's Efdoralprin Alfa gained orphan status from the EMA for treating emphysema linked to Alpha-1 Antitrypsin Deficiency, meeting all Phase 2 study endpoints. Data will be presented soon.1Sanofi will pay $7.5 million to Cytokinetics following the approval of Myqorzo for obstructive hypertrophic cardiomyopathy in China, where Sanofi holds exclusive rights.2Sanofi has not accepted the most-favored-nation pricing for drugs, aligning with eleven other pharma firms, while Pfizer, Eli Lilly, AstraZeneca, Novo Nordisk, and EMD Serono have agreed.3
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments